Vimarsana
Biggest News Aggregation in the World

Page 44 - Incheon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Incheon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Incheon Today - Breaking & Trending Today

South Korean construction firms tighten belts to overcome downturn in housing construction market - Vimarsana News

South Korean construction firms tighten belts to overcome downturn in housing construction market

SK ecoplant recently nominated SK E&S Chief Financial Officer Kim Hyung-keun as the new CEO to improve its financial soundness and pursue an initial public offering (IPO). The decision came as a surprise because SK Group has tended to replace the top executives of its affiliates during annual year-end reshuffles.

Provincial students to gain wider access to med schools - Vimarsana News

Provincial students to gain wider access to med schools

For aspiring medical doctors in South Korea, where they live is likely to play a major factor in shaping their chances of entering medical school, as the new admissions plan envisions clear advantages for students living outside the capital. According to the Korean Council for University Education and universities, out of the total 4,567 enrollments set for the nation’s 40 medical schools in the 2025 academic y...

Inside Boeing tragedy - Vimarsana News

Inside Boeing tragedy

It's believed the clear-air turbulence that impacted flight SQ321 would not have been picked up on its state of the art Honeywell IntuVue 3D weather radar - a system used on many 777s.

Five of the best new cruise routes will take you to truly unusual places - Vimarsana News

Five of the best new cruise routes will take you to truly unusual places

From ice-encrusted mountains to jungle-clad volcanoes, glamorous Asian cities to the remotest settlements, here are five of the most tempting new cruise routes.

Source: smh.com.au
Celltrion receives European Commission approval of Omlyclo (CT-P39), the first and only omalizumab biosimilar approved in Europe - Vimarsana News

Celltrion receives European Commission approval of Omlyclo (CT-P39), the first and only omalizumab biosimilar approved in Europe

Omlyclo (CT-P39), used to treat allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic spontaneous urticaria (CSU), becomes the first omalizumab biosimilar approved in the